ERBB2 and neoplasm: It integrates tumor-intrinsic biology with clinical features to provide a genomic risk score (i.e., HER2DX risk-score) for long-term outcomes, as well as additional biologically driven metrics such as a pathologic complete response (pCR) likelihood score (i.e., HER2DX pCR-score) and an ERBB2 expression score15,18.